Table 1 Patient and treatment characteristics
From: Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma
Characteristics | Value/number (%) |
|---|---|
Patient number | 30 |
Gender | |
Male | 17 (57) |
Female | 13 (43) |
Treatment time | 07/2004–04/2017 |
Age at diagnosis, median (range) | 45.8 (23.2–69.4) |
< 40 | 10 (33) |
40–< 60 | 15 (50) |
60–< 70 | 5 (17) |
WHO grade | |
Primary tumor | Grade II: 1 |
Grade III: 1 | |
Grade IV: 28 (93) | |
Recurrent tumor | Grade III: 1 |
Grade IV: 29 (97) | |
Molecular markers | |
MGMT methylation | 13/30 (43) |
IDH1/2 mutation | 8/30 (27) |
ATRX mutation | 9/30 (30) |
Treatment, 1st line | |
Surgery only | 2 |
Surgery + adjuvant radio-chemotherapy | 27 (90) |
Surgery + adjuvant radiotherapy | 1 |
Treatment, 2nd line | |
Surgery only | 4 (13) |
Surgery + radio-chemotherapy | 7 (23) |
Surgery + radiotherapy | 2 (7) |
Surgery + chemotherapy | 17 (57) |
Median time from first to second surgery (months, range) | 8.1 (3.4–72.8) |
Median follow-up (months) | 24.0 |
Vital status at last follow up | |
Alive | 7 (23) |
Dead | 23 (77) |